You are hereNovember 3, 2020
Engineered Cardiopoietic Stem Cell Therapy
A new STEM CELLS Translational Medicine study from the laboratory of Atta Behfar (Mayo Clinic, Rochester, MN, USA) reported the engineering of cardiac repair competent stem cells using Brachyury, a mesodermal transcription factor. Li et al. demonstrated how the transfection of Brachyury using the microencapsulated‐modified‐mRNA technique induced naïve mesenchymal stem cells to adopt a cardiopoietic fate endowed with cardioreparative ability. The traditional cardiopoiesis process generally requires multiple recombinant proteins; however, this new streamlined single‐gene approach may simplify the cell procurement process and allow for rapid clinical translation.